Engineered T-Cells take aim at bladder, skin, and head and neck cancers
NCT ID NCT02989064
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether genetically modified T-cells (MAGE-A10ᶜ⁷⁹⁶T) are safe for people with advanced urothelial cancer, melanoma, or head and neck cancer. Ten participants received their own engineered immune cells after chemotherapy. The main goal was to check for side effects and find the right dose, not to prove the treatment works. Researchers will follow participants for 15 years to monitor long-term effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified T-cells (MAGE-A10ᶜ⁷⁹⁶T)
What this could lead to
If successful, this could lead to a new treatment option for certain hard-to-treat cancers by training the immune system to attack tumors.
What could go wrong
This is a very early Phase 1 trial with only 10 participants, so safety and effectiveness are not yet proven. The treatment may cause serious side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Hospital Universitario 12 Octubre Avda. de Córdoba
Madrid, 28041, Spain
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G1X6, Canada
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Start Madrid-FJD, Fundación Jimѐnez Díaz
Madrid, 28040, Spain
-
Tennessee Oncology - Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee, 37203, United States
-
Washington University - School of Medicine
St Louis, Missouri, 63110, United States